IMINO-OXAZOLIDINES AND USE THEREOF
The present invention relates to novel iminooxazolidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.
1 . Compound of the formula (I)
in which
A represents a group of the formula
in which
R 4 represents hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy, (C 1 -C 6 )-alkoxy, amino, mono- or di-(C 1 -C 6 )-alkylamino, (C 3 -C 7 )-cycloalkylamino, (C 1 -C 6 )-alkanoylamino or (C 1 -C 6 )-alkoxy-carbonylamino, where
(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, mono- and di-(C 1 -C 6 )-alkylamino for their part may in each case be substituted by hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono- or di-(C 1 -C 4 )-alkylamino, (C 3 -C 7 )-cycloalkylamino or a 4- to 7-membered saturated heterocycle which is attached via a nitrogen atom and which may contain a ring member from the group consisting of N—R 5 and O, where
R 5 represents hydrogen or (C 1 -C 4 )-alkyl,
and * denotes the point of attachment to the phenyl ring,
or
A represents a group of the formula —C(═O)—NR 6 R 7 , where
R 6 and R 7 are identical or different and independently of one another are (C 1 -C 6 )-alkyl or (C 3 -C 7 )-cycloalkyl
or
R 6 and R 7 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated or partially unsaturated heterocycle which may contain one ring member from the group consisting of N—R 8 and O and which may be substituted by (C 1 -C 6 )-alkyl, hydroxy, (C 1 -C 6 )-alkoxy, oxo, amino, mono- or di-(C 1 -C 6 )-alkylamino, where
R 8 represents hydrogen or (C 1 -C 6 )-alkyl,
where for their part all (C 1 -C 6 )-alkyl groups mentioned may be substituted by hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono- or di-(C 1 -C 4 )-alkylamino or (C 3 -C 7 )-cycloalkylamino,
Z represents phenyl, pyridyl, pyrimidinyl, pyrazinyl, thienyl, furyl or pyrrolyl which may in each case be mono- or disubstituted by identical or different substituents selected from the group consisting of halogen, cyano, (C 1 -C 4 )-alkyl, which for its part may be substituted by hydroxyl or amino, ethynyl, cyclopropyl and amino,
R 1 and R 2 are identical or different and independently of one another represent hydrogen, halogen, cyano, (C 1 -C 4 )-alkyl, cyclopropyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, amino, mono- or di-(C 1 -C 4 )-alkyl-amino, where
(C 1 -C 4 )-alkyl and (C 1 -C 4 )-alkoxy for their part may in each case be substituted by hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono- or di-(C 1 -C 4 )-alkylamino or (C 3 -C 7 )-cycloalkylamino,
and
R 3 represents hydrogen, (C 1 -C 6 )-alkyl or cyano,
and salts, solvates and solvates of the salts thereof.
2 . A compound of the formula (I) according to claim 1 in which
A represents a group of the formula
in which
R 4A represent hydrogen, hydroxyl, methoxy or amino,
R 4B represents methyl or ethyl which may in each case be substituted by hydroxyl, amino, pyrrolidino or cyclopropylamino, or represents amino,
R 4C represents hydrogen, methyl or ethyl, where methyl and ethyl may in each case be substituted by hydroxyl, amino, pyrrolidino or cyclopropylamino,
and
* denotes the point of attachment to the phenyl ring,
Z represents a group of the formula
in which
R 9 represents fluorine, chlorine, methyl or ethynyl
and
# denotes the point of attachment to the carbonyl group,
R 1 represents hydrogen,
R 2 represents hydrogen, fluorine or methyl,
and
R 3 represents hydrogen or (C 1 -C 4 )-alkyl,
and salts, solvates and solvates of the salts thereof.
3 . A compound of the formula (I) according to claim 1 in which
A represents a group of the formula
in which * denotes the point of attachment to the phenyl ring,
Z represents a group of the formula
in which
R 9 represents fluorine, chlorine or methyl
and
# denotes the point of attachment to the carbonyl group,
R 1 represents hydrogen,
R 2 represents hydrogen, fluorine or methyl,
and
R 3 represents hydrogen,
and salts, solvates and solvates of the salts thereof.
4 . A method for preparing compounds of the formula (I) as defined in claim 1 in which R 3 represents hydrogen, characterized in that (2S)-3-aminopropane-1,2-diol of the formula (II)
is reacted in an inert solvent in the presence of a base with a compound of the formula (III)
in which Z has the meaning given in claim 1 and
X represents a suitable leaving group such as, for example, halogen, preferably chlorine,
to give compounds of the formula (IV)
in which Z has the meaning given above,
then converted with the aid of hydrobromic acid in acetic acid, if appropriate with addition of acetic anhydride, into compounds of the formula (V)
in which Z has the meaning given above,
these are then cyclized in an inert solvent in the presence of a base into compounds of the formula (VI)
in which Z has the meaning given above,
then reacted in an inert solvent, if appropriate in the presence of a protic acid or Lewis acid, with a compound of the formula (VII)
in which A, R 1 and R 2 have the meanings given in claim 1 , to give compounds of the formula (VIII)
in which A, Z, R 1 and R 2 have the meanings given above,
and these are then reacted in an inert solvent with cyanogen bromide, if appropriate in the presence of an acid, to give compounds of the formula (I-A)
in which A, Z, R 1 and R 2 have the meanings given above,
and the compounds of the formula (I-A) are, if appropriate, converted with the appropriate (i) solvents and/or (ii) bases or acids into their solvates, salts and/or solvates of the salts.
5 . A compound of the formula (I) as defined in claim 1 for the treatment and/or prophylaxis of diseases.
6 . (canceled)
7 . (canceled)
8 . A pharmaceutical composition comprising a compound of the formula (I) as defined in claim 1 in combination with an inert non-toxic, pharmaceutically suitable auxiliary.
9 . The pharmaceutical composition of claim 8 further comprising a second active compound.
10 . The pharmaceutical composition of claim 8 for the treatment and/or prophylaxis of thromboembolic disorders.
11 . A method for the treatment and/or prophylaxis of thromboembolic disorders in humans and animals, comprising administering an anticoagulatory effective amount of at least one compound of the formula (I) as defined in claim 1 .
12 . A method for preventing blood coagulation in vitro, comprising administering an anticoagulatory effective amount of a compound of the formula (I) as defined in claim 1 is added.
13 . A method for the treatment and/or prophylaxis of thromboembolic disorders in humans and animals, comprising administering an anticoagulatory effective amount of a pharmaceutical composition of claim 8 .